Facility fees

Reader David States sent me two articles on facility fees, a topic I’ve not given much attention (yet). Liz Kowalczyk reported in January 2013: [T]he

READ MORE

Policy commentary and peer review

The psychologist Jay Belsky has a provocative editorial in this morning’s New York Times. For reasons that will be come clear in a moment, I can’t comment

READ MORE

Targeting drug development

Muthiah Vaduganathan and Vinay Prasad in a JAMA Viewpoint: From a pragmatic standpoint, drug development programs conducted in broad populations poorly prioritize which patients should start therapy first. If

READ MORE

The formulary wars

Robert Langreth reports: Unless more is done about a wave of new and expensive drugs, some priced at as much as $50,000 a month, Miller

READ MORE

Regulating innovation

Paul Demko reports: [CMS] wants to require insurers to establish “pharmacy and therapeutics” committees that would meet at least four times a year to review drug

READ MORE

Is Pay for Performance Corrupting Medicine?

Pamela Hartzband and Jerome Groopman have a recent New York Times editorial arguing that quality incentives for doctors are corrupting medicine: [F]inancial forces largely hidden from the public are beginning

READ MORE
Subscribe

Email Address*